Since its conception, biotechnology company Chinook Therapeutics, Inc. ("Chinook") has worked to develop therapeutic solutions for patients with kidney diseases. Now, the company enrolled the first patient in a…
Evotec SE and Chinook Therapeutics have entered into a strategic partnership in an effort to find, create, and develop viable treatments for those living with chronic kidney diseases. Under the…
Immunoglobulin A nephropathy (IgAN) is a glomerular disease which can lead to kidney failure. Between 70 and 100 percent of all IgAN patients also are diagnosed with microscopic hematuria, but…
by Lauren Taylor from In The Cloud Copy Nephrologists worldwide have shown that there is a huge unmet need when it comes to the treatment of various glomerular diseases, in…
On December 9th, 2020, a special edition of "Behind the Mystery: Rare and Genetic" will air on Lifetime TV as part of the acclaimed morning program The Balancing Act. It…
According to a story from pharmalive.com, the drug company Calliditas Therapeutics will plan to seek approval for its therapy Nefecon from the US Food and Drug Administration (FDA). This approval…
Recently, biopharmaceutical company Everest Medicines ("Everest") announced positive topline data from the Phase 3 NefIgArd trial, which was run by its licensing partner Calliditas Therapeutics AB ("Calliditas"). Together, the…
According to a story from Newswise, a recent study concluded that adult patients living with glomerular diseases face an increased chance of cardiovascular disease as well. The findings were first…
On May 28th, biopharmaceutical company Bird Rock Bio filed an IND application to perform a Phase II clinical study to determine the efficacy and tolerability of nimacimab. The company hopes…
According to a story from Yahoo Finance, the biopharmaceutical company Mallinckrodt recently released findings from an open label pilot study which tested the impact of Acthar Gel (corticotropin injection) as…
Apellis Pharmaceuticals has just announced that they have received Orphan Drug Designation from the FDA for APL-2, a C3 complement inhibitor. The company is currently investigating the drug as a…
According to a story from BioSpace, the biopharmaceutical company Retrophin, Inc., recently announced that the first patient has been treated in the company's Phase 3 clinical trial testing sparsentan as…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
